Insmed Inc (INSM)
73.54
+1.85
(+2.58%)
USD |
NASDAQ |
Nov 08, 16:00
74.00
+0.46
(+0.63%)
After-Hours: 17:05
Insmed Revenue (TTM): 342.96M for Sept. 30, 2024
Revenue (TTM) Chart
Historical Revenue (TTM) Data
Date | Value |
---|---|
September 30, 2024 | 342.96M |
June 30, 2024 | 328.60M |
March 31, 2024 | 315.49M |
December 31, 2023 | 305.21M |
September 30, 2023 | 280.82M |
June 30, 2023 | 269.47M |
March 31, 2023 | 257.46M |
December 31, 2022 | 245.36M |
September 30, 2022 | 242.18M |
June 30, 2022 | 221.21M |
March 31, 2022 | 201.35M |
December 31, 2021 | 188.46M |
September 30, 2021 | 173.75M |
June 30, 2021 | 170.64M |
March 31, 2021 | 167.77M |
December 31, 2020 | 164.41M |
September 30, 2020 | 168.71M |
June 30, 2020 | 163.95M |
March 31, 2020 | 151.42M |
December 31, 2019 | 136.47M |
September 30, 2019 | 100.59M |
June 30, 2019 | |
March 31, 2019 | |
December 31, 2018 | |
September 30, 2018 |
Date | Value |
---|---|
June 30, 2018 | |
March 31, 2018 | |
December 31, 2017 | |
September 30, 2017 | |
June 30, 2017 | |
March 31, 2017 | |
December 31, 2016 | |
September 30, 2016 | |
June 30, 2016 | |
March 31, 2016 | |
December 31, 2015 | |
September 30, 2015 | |
June 30, 2015 | |
March 31, 2015 | |
December 31, 2014 | |
September 30, 2014 | |
June 30, 2014 | |
March 31, 2014 | |
December 31, 2013 | |
September 30, 2013 | |
June 30, 2013 | |
March 31, 2013 | |
December 31, 2012 | |
September 30, 2012 | |
June 30, 2012 |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (TTM) Range, Past 5 Years
136.47M
Minimum
Dec 2019
342.96M
Maximum
Sep 2024
224.78M
Average
211.28M
Median
Revenue (TTM) Benchmarks
Fulcrum Therapeutics Inc | -- |
Alnylam Pharmaceuticals Inc | 2.095B |
Eli Lilly and Co | 40.86B |
Bioventus Inc | 555.06M |
Entrada Therapeutics Inc | 215.23M |